Summary of study ST000995

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000675. The data can be accessed directly via it's Project DOI: 10.21228/M8DX19 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  |  Download all metabolite data  |  Download mwTab file (text)   |  Download mwTab file(JSON)
Study IDST000995
Study TitleAmino Acid Concentrations of Primary Sclerosing Cholangitis (part I)
Study SummaryTo qualitatively and quantitatively analyze enterohepatically-circulated molecules using targeted amino acid concentrations of peripheral blood collected from primary sclerosing cholangitis (PSC) patients compared to normal and diseased controls. There are three groups of patients. (1) Normal donor controls (ND), (2) Patients with Primary Sclerosing Cholangitis (PSC), and (3) Disease Controls (DC) which are patients with liver disease other than PSC.
Institute
Mayo Clinic
Last NameO'Hara
First NameSteven
Address200 First St. SW, Rochester, Minnesota, 55905, USA
Emailohara.steven@mayo.edu
Phone507-284-1006
Submit Date2018-07-05
Raw Data AvailableYes
Raw Data File Type(s).raw
Analysis Type DetailLC-MS
Release Date2019-07-17
Release Version1
Steven O'Hara Steven O'Hara
https://dx.doi.org/10.21228/M8DX19
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Project:

Project ID:PR000675
Project DOI:doi: 10.21228/M8DX19
Project Title:Mayo Pilot and Feasibility: The Enterohepatic Metabolome in Primary Sclerosing Cholangitis
Project Summary:Emerging in vitro and in vivo data, including work from our laboratory and clinical research group, suggest fundamental pathophysiologic mechanisms in primary sclerosing cholangitis (PSC) that are centered on the enterohepatic circulation of gut-derived molecules. Therefore, in this proposal, we will test the central hypothesis that increased pathologic enterohepatic circulation of enteric metabolites which trigger specific pro-fibroinflammatory hepatobiliary responses are centrally involved in the etiopathogenesis of primary sclerosing cholangitis (PSC). While these processes have been hypothesized to play a significant role in the initiation, progression, and adverse clinical sequelae of PSC, they have not been directly tested to date. In our proposal, we will experimentally address the nature and extent of the metabolomic profiles of portal and peripheral blood as well as bile in patients with PSC. We will perform qualitative and quantitative ultra-performance liquid chromatography/mass spectroscopy-based metabolomic analyses to determine metabolic changes in portal and peripheral plasma and bile. Through subsequent pathway analyses we intend to identify metabolic enzymes and known biochemical pathways that may be altered in PSC. We anticipate that patients with PSC will have distinct alterations in the portal venous and bile metabolomic profiles and associated signaling pathways compared to normal and disease controls; and these alterations may be amenable to pharmacologic manipulation and future therapies.
Institute:Mayo Clinic
Last Name:O'Hara
First Name:Steven
Address:200 First St. SW, Rochester, Minnesota, 55905, USA
Email:ohara.steven@mayo.edu
Phone:507-284-1006

Subject:

Subject ID:SU001034
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Grouping
SA061645ms6721-23DC
SA061646ms6721-24DC
SA061647ms6721-25DC
SA061648ms6721-22DC
SA061649ms6721-21DC
SA061650ms6721-19DC
SA061651ms6721-20DC
SA061652ms6721-26DC
SA061653ms6721-27DC
SA061654ms6721-32DC
SA061655ms6721-33DC
SA061656ms6721-31DC
SA061657ms6721-30DC
SA061658ms6721-28DC
SA061659ms6721-29DC
SA061660ms6721-18DC
SA061661ms6721-17DC
SA061662ms6721-16DC
SA061663ms6721-1ND
SA061664ms6721-9ND
SA061665ms6721-8ND
SA061666ms6721-6ND
SA061667ms6721-4ND
SA061668ms6721-2ND
SA061669ms6721-3ND
SA061670ms6721-7ND
SA061671ms6721-5ND
SA061672ms6721-10PSC
SA061673ms6721-15PSC
SA061674ms6721-14PSC
SA061675ms6721-13PSC
SA061676ms6721-12PSC
SA061677ms6721-11PSC
Showing results 1 to 33 of 33

Collection:

Collection ID:CO001028
Collection Summary:After obtaining informed consent, portal and peripheral venous blood (4 ml of each) and bile (2 mL) was collected intraoperatively in a red-top tube by a Mayo Clinic LT surgeon. Blood was placed on ice, promptly fractionated by centrifugation, divided into 100 μL aliquots, and stored at -80°C.
Sample Type:Blood (serum)

Treatment:

Treatment ID:TR001048
Treatment Summary:" We prospectively enrolled three groups of participants from the Mayo Clinic Liver Transplant inpatient service and outpatient clinics and have collected samples from: i) 9 patients with PSC who underwent living- donor LT, ii) 15 donors (normal controls), and iii) 20 patients with cirrhosis due to a disorder other than PSC who underwent LT (disease controls). The following inclusion and exclusion criteria were applied: Inclusion criteria 1. Adult (age>18 years). 2. PSC patient undergoing LT, healthy living donor, or other chronic liver disease patient undergoing LT. Exclusion Criteria: 1. Females who are pregnant or attempting to become pregnant. 2. Concomitant liver disease (e.g. chronic viral hepatitis in addition to PSC). 3. Acute intestinal disease (infectious enterocolitis, IBD flare) in the past 6 months. 4. Treatment with any investigational drugs within the past 6 months. 5. Use of antibiotics within the past 4 weeks. 6. Any previous organ transplant. 7. Hemodialysis."

Sample Preparation:

Sampleprep ID:SP001041
Sampleprep Summary:amino acid concentrations

Combined analysis:

Analysis ID AN001624
Analysis type MS
Chromatography type Reversed phase
Chromatography system Waters Acquity
Column Waters Acquity BEH C18 (150 x 2.1mm, 1.7um)
MS Type ESI
MS instrument type Triple quadrupole
MS instrument name Thermo Quantum Ultra
Ion Mode POSITIVE
Units uM

Chromatography:

Chromatography ID:CH001142
Instrument Name:Waters Acquity
Column Name:Waters Acquity BEH C18 (150 x 2.1mm, 1.7um)
Chromatography Type:Reversed phase

MS:

MS ID:MS001500
Analysis ID:AN001624
Instrument Name:Thermo Quantum Ultra
Instrument Type:Triple quadrupole
MS Type:ESI
MS Comments:uM
Ion Mode:POSITIVE
  logo